The use of thalidomide in myeloma therapy as an effective anticancer drug

Current Cancer Drug Targets

Volumn 6, Issue 4, 2006, Pages 325-331

  Sze, Daniel M Y ^a   Brown, Ross ^a   Yang, Shihong ^a   Ho, P Joy ^a   Gibson, John ^a   Joshua, Douglas ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOMODULATING AGENT; MELPHALAN; THALIDOMIDE;

ANTIANGIOGENIC ACTIVITY; BEHCET DISEASE; BONE MARROW CELL; BONE METABOLISM; CELL ADHESION; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; ERYTHEMA NODOSUM LEPROSUM; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; MICROENVIRONMENT; MORNING SICKNESS; MOUTH ULCER; MYELOMA; NATURAL KILLER CELL; NONHUMAN; REVIEW; SKIN DEFECT; STROMA CELL; T LYMPHOCYTE; TERATOGENICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE REMODELING; CELL PROLIFERATION; HUMANS; KILLER CELLS, NATURAL; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES; THALIDOMIDE;

EID: 33745500974     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800906777441762     Document Type: Review

References (84)

1. Sze, D. M.; Toellner, K. M.; Garcia de Vinuesa, C.; Taylor, D. R.; MacLennan, I. C. Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J. Exp. Med. 2000, 192, 813-821.
2. Joshua, D. E.; Gibson, J. Multiple myeloma - evolving concepts of biology and treatment. Aust. N. Z. J. Med. 2000, 30, 311-318.
3. Alexanian, R.; Dimopoulos, M. The treatment of multiple myeloma. N. Engl. J. Med. 1994, 330, 484-489.
4. Lenz, W. Thalidomide and congenital abnormalities. Lancet 1962, 1, 45.
5. Sheskin, J. Thalidomide in the Treatment of Lepra Reactions. Clin. Pharmacol. Ther. 1965, 40, 303-306.
6. Rajkumar, S.; Mesa, R. A,; Tefferi, A. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. J. Hematother. Stem Cell Res. 2002, 11, 33-47.
7. Grabstald, H.; Golbey, R. Clinical experiences with thalidomide in patients with cancer. Clin. Pharmacol. Ther. 1965, 40, 298-302.
8. Olson, K.; Hall, T. C.; Horton, J.; Khung, C. L.; Hosley, H. F. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin. Pharmacol. Ther. 1965, 6, 292-297.
9. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumour activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999, 341, 1565-1571.
10. Barlogie, B.; Desikan, R.; Eddlemon, P.; Spencer, T.; Zeldis, J.; Munshi, N.; Badros, A.; Zangari, M.; Anaissie, E.; Epstein, J.; Shaughnessy, J.; Ayers, D.; Spoon, D.; Tricot, G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98, 492-494.
11. Rajkumar, S.; Fonseca, R.; Dispenzieri, A.; Lacy, M. Q.; Lust, J. A.; Witzig, T. E.; Kyle, R. A.; Gertz, M. A.; Greipp, P. R. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin. Proc. 2000, 75, 897-901.
12. Dimopoulos, M.; Anagnostopoulos, A.; Weber, D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J. Clin. Oncol. 2003, 21, 4444-4454.
13. Kumar, A.; Loughran, T.; Alsina, M.; Durie, B. G.; Djulbegovic, B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol. 2003, 4, 293-304.
14. Palumbo, A.; Giaccone, L.; Bertola, A.; Pregno, P.; Bringhen, S.; Rus, C.; Triolo, S.; Gallo, E.; Pileri, A.; Boccadoro, M. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001, 86, 399-403.
15. Anagnostopoulos, A.; Weber, D.; Rankin, K.; Delasalle, K.; Alexanian, R. Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol. 2003, 121, 768-771.
16. Garcia-Sanz, R.; Gonzalez-Fraile, M.I.; Sierra, M.; Lopez, C.; Gonzalez, M.; San Miguel, J. F. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol. J. 2002, 3, 43-48.
17. Srkalovic, G.; Elson, P.; Trebisky, B.; Karam, M. A.; Hussein, M. A. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med. Oncol. Tumor Pharmacother. 2002, 19, 219-226.
18. Corral, L. G.; Haslett, P. A.; Muller, G. W.; Chen, R.; Wong, L. M.; Ocampo, C. J.; Patterson, R. T.; Stirling, D. I.; Kaplan, G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. 1999, 163, 380-386.
19. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Chauhan, D.; Richardson, P. G.; Hideshima, T.; Munshi, N. C.; Treon, S. P.; Anderson, K. C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99, 4525-4530.
20. Hideshima, T.; Chauhan, D.; Shima, Y.; Raje, N.; Davies, F. E.; Tai, Y. -T.; Treon, S. P.; Lin, B.; Schlossman, R. L.; Richardson, P.; Muller, G.; Stirling, D. I.; Anderson, K. C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96, 2943-2950.
21. Parman, T.; Wiley, M. J.; Wells, P. G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. 1999, 5, 582-585.
22. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 1994, 91, 4082-4085.
23. Neben, K.; Moehler, T.; Kraemer, A.; Benner, A.; Egerer, G.; Ho, A. D.; Goldschmidt, H. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br. J. Haematol. 2001, 115, 605-608.
24. Bauer, K.; Dixon, S. C.; Figg, W. D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 1998, 55, 1827-1834.
25. Damiano, J. S.; Cress, A. E.; Hazlehurst, L. A.; Shtil, A. A.; Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93, 1658-1667.
26. Shain, K. H.; Landowski, T. H.; Dalton, W. S. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 2002, 168, 2544-2553.
27. Hazlehurst, L. A.; Damiano, J. S.; Buyuksal, I.; Pledger, W. J.; Dalton, W. S. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000, 19, 4319-4327.
28. Sampaio, E. P.; Sarno, E. N.; Galilly, R.; Cohn, Z. A.; Kaplan, G. Thalidomide selectively inhibits tumour necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 1991, 173, 699-703.
29. Sampaio, E. P.; Kaplan, G.; Miranda, A.; Nery, J. A.; Miguel, C. P.; Viana, S. M.; Sarno, E. N. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 1993, 168, 408-414.
30. Tramontana, J. M.; Utaipat, U.; Molloy, A.; Akarasewi, P.; Burroughs, M.; Makonkawkeyoon, S.; Johnson, B.; Klausner, J. D.; Rom, W.; Kaplan, G. Thalidomide treatment reduces tumour necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. 1995, 1, 384-397.
31. Uchiyama, H.; Barut, B. A.; Mohrbacher, A. F.; Chauhan, D.; Anderson, K. C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993, 82, 3712-3720.
32. Richardson, P. G.; Schlossman, R. L.; Weller, E.; Hideshima, T.; Mitsiades, C.; Davies, F.; LeBlanc, R.; Catley, L. P.; Doss, D.; Kelly, K.; McKenney, M.; Mechlowicz, J.; Freeman, A.; Deocampo, R.; Rich, R.; Ryoo, J. J.; Chauhan, D.; Balinski, K.; Zeldis, J.; Anderson, K. C. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100, 3063-3067.
33. Field, E. O.; Gibbs, J. E.; Tucker, D. F.; Hellmann, K. Effect of thalidomide on the graft versus host reaction. Nature 1966, 211, 1308-1310.
34. Vogelsang, G. B.; Hess, A. D.; Gordon, G.; Brundrette, R.; Santos, G. W. Thalidomide induction of bone marrow transplantation tolerance. Transplant. Proc. 1987, 19, 2658-2661.
35. Vogelsang, G. B.; Hess, A. D.; Gordon, G.; Santos, G. W. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation 1986, 41, 644-647.
36. Vogelsang, G. B.; Farmer, E. R.; Hess, A. D.; Altamonte, V.; Beschorner, W. E.; Jabs, D. A.; Corio, R. L.; Levin, L. S.; Colvin, O. M.; Wingard, J. R.; Santos, G. W. Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. 1992, 326, 1055-1058.
37. McCarthy, D. M.; Kanfer, E. J.; Barrett, A. J. Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation. Biomed. Pharmacother. 1989, 43, 693-697.
38. Keenan, R. J.; Eiras, G.; Burckart, G. J.; Stuart, R. S.; Hardesty, R. L.; Vogelsang, G.; Griffith, B. P.; Zeevi, A. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. Transplantation 1991, 52, 908-910.
39. Coulson, A. S.; Summers, L. J.; Lindahl-Kiessling, K.; Tucker, D.; Hellmann, K. The effect of two soluble thalidomide derivatives on lymphocyte stimulation. Clin. Exp. Immunol. 1970, 7, 241-247.
40. Fernandez, L. P.; Schlegel, P. G.; Baker, J.; Chen, Y.; Chao, N. J. Does thalidomide affect IL-2 response and production? Exp. Hematol. 1995, 23, 978-985.
41. Massaia, M.; Borrione, P.; Battaglio, S.; Mariani, S.; Beggiato, E.; Napoli, P.; Voena, C.; Bianchi, A.; Coscia, M.; Besostri, B.; Peola, S.; Stiefel, T.; Even, J.; Novero, D.; Boccadoro, M.; Pileri, A. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999, 94, 673-683.
42. Lim, S. H.; Wen, Y. J.; Ling, M. Malignancy: Idiotypic Immune Targeting of Multiple Myeloma. Hematol. 2000, 4, 471-477.
43. Liso, A.; Stockerl-Goldstein, K. E.; Auffermann-Gretzinger, S.; Benike, C. J.; Reichardt, V.; van Beckhoven, A.; Rajapaksa, R.; Engleman, E. G.; Blume, K. G.; Levy, R. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant 2000, 6, 621-627.
44. Cull, G. M.; Carter, G. I.; Timms, J. M.; Thomson, B. J.; Russell, N. H.; Haynes, A. P. Low incidence of human herpesvirus 8 in stem cell collections from myeloma patients. Bone Marrow Transplant 1999, 23, 759-761.
45. Osterborg, A.; Henriksson, L.; Mellstedt, H. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma. Acta Oncol. 2000, 39, 797-800.
46. Reichardt, V. L.; Okada, C. Y.; Liso, A.; Benike, C. J.; Stockerl-Goldstein, K. E.; Engleman, E. G.; Blume, K. G.; Levy, R. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study. Blood 1999, 93, 2411-2419.
47. Titzer, S.; Christensen, O.; Manzke, O.; Tesch, H.; Wolf, J.; Emmerich, B.; Carsten, C.; Diehl, V.; Bohlen, H. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br. J. Haematol. 2000, 108, 805-816.
48. Lacy, M. Q.; Wettstein, P.; Gastineau, D. A.; Greipp, P. R.; Fonseca, R.; Dispenzieri, A.; Lust, J.; Witzig, T.; Rajkumar, S. V.; Valone, F.; Kyle, R. A.; Gertz, M. A. Dendritic cell-based idiotype vaccination in post transplant multiple myeloma. Blood 1999, 94, 122a.
49. MacKenzie, M.; Peshwa, M. V.; Wun, T.; Strang, G.; Wolf, J.; Gutheil, J.; Mason, J.; Caggiano, V.; Valone, F. H. Efficacy of idiotype-pulsed autologous dendritic cells for treatment of advanced refractory multiple myeloma. Blood 1999, 94, 122a.
50. Trojan, A.; Schultze, J. L.; Witzens, M.; Vonderheide, R. H.; Ladetto, M.; Donovan, J. W.; Gribben, J. G. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat. Med. 2000, 6, 667-672.
51. Sze, D. M.; Brown, R. D.; Yang, S.; Gibson, J.; Ho, J.; de St Groth, B. F.; Basten, A.; Joshua, D. E. Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leuk. Lymphoma 2003, 44, 1557-1568.
52. Treon, S. P.; Mollick, J. A.; Urashima, M.; Teoh, G.; Chauhan, D.; Ogata, A.; Raje, N.; Hilgers, J. H.; Nadler, L.; Belch, A. R.; Pilarski, L. M.; Anderson, K. C. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999, 93, 1287-1298.
53. Pellat-Deceunynck, C.; Mellerin, M. P.; Labarriere, N.; Jego, G.; Moreau-Aubry, A.; Harousseau, J. L.; Jotereau, F.; Bataille, R. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur. J. Immunol. 2000, 30, 803-809.
54. Lim, S. H.; Wang, Z.; Chiriva-Internati, M.; Xue, Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001, 97, 1508-1510.
55. Nogueira, A. C.; Neubert, R.; Helge, H.; Neubert, D. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci. 1994, 55, 77-92.
56. McHugh, S. M.; Rifkin, I. R.; Deighton, J.; Wilson, A. B.; Lachmann, P. J.; Lockwood, C. M.; Ewan, P. W. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol. 1995, 99, 160-167.
57. Moller, D. R.; Wysocka, M.; Greenlee, B. M.; Ma, X.; Wahl, L.; Flockhart, D. A.; Trinchieri, G.;Karp, C. L. Inhibition of IL-12 production by thalidomide. J. Immunol. 1997, 159, 5157-5161.
58. Eriksson, T.; Bjorkman S, H. P. Clinical pharmacology of thalidomide. Eur. J. Clin. Pharmacol. 2001, 57, 365-376.
59. Raitakari, M.; Brown, R.D.; Sze, D. M.; Yuen, E.; Barrow, L.; Nelson, M.; Pope, B.; Esdale, W.; Gibson, J.; Joshua, D.E. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br. J. Haematol. 2000, 110, 203-209.
60. Sze, D. M. -Y.; Giesajtis, G.; Brown, R. D.; Raitakari, M.; Gibson, J.; Ho, J.; Baxter A. G.; Fazekaas de St Groth, B.; Basten, A.; Joshua, D. E. Clonal Cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28- compartment. Blood 2001, 98, 2817-2827.
61. Sze, D. M. -Y.; Brown, R; Yang, S.; Ho, J. P.; Gibson, J.; Fazekas de St Groth, B.; Basten, A.; Joshua, D. Clonally Expanded T Cells in Myeloma with a Late Memory/Effector Phenotype Are Associated with Improved Survival. Blood 2004, 102, 927a.
62. Sze, D. M.; Brown, R. D.; Yuen, E.; Gibson, J.; Ho, J.; Raitakari, M.; Basten, A.; Joshua, D. E.; Fazekas de St Groth, B. Clonal cytotoxic T cells in myeloma. Leuk. Lymphoma 2003, 44, 1667-1674.
63. Haslett, P. A. J.; Corral, L. G.; Albert, M.; Kaplan, G. thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 1998, 187, 1885-1892.
64. Waters, M. F. An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr. Rev. 1971, 42, 26-42.
65. Haslett, P. A.; Klausner, J. D.; Makonkawkeyoon, S.; Moreira, A.; Metatratip, P.; Boyle, B.; Kunachiwa, W.; Maneekarn, N.; Vongchan, P.; Corral, L. G.; Elbeik, T.; Shen, Z.; Kaplan, G. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res. Hum. Retroviruses 1999, 15, 1169-1179.
66. Davies, F. E.; Raje, N.; Hideshima, T.; Lentzsch, S.; Young, G.; Tai, Y. -T.; Lin, B.; Podar, K.; Gupta, D.; Chauhan, D.; Treon, S. P.; Richardson, P. G.; Schlossman, R. L.; Morgan, G. J.; Muller, G. W.; Stirling, D. I.; Anderson, K. C. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98, 210-216.
67. Murray, A.; Brown, R.; Ho, P. J.; Sze, D.; Gibson, J.; Joshua, D. Increased number of TCR Vβ expansions in patients on Thalidomide maintenance therapy provides further evidence of the immunomodulatory action of Thalidomide. Hematologica 2005, 90(S1), 182.
68. LeBlanc, R.; Hideshima, T.; Catley, L. P.; Shringarpure, R.; Burger, R.; Mitsiades, N.; Mitsiades, C.; Cheema, P.; Chauhan, D.; Richardson, P. G.; Anderson, K. C.; Munshi, N. C. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004, 103, 1787-1790.
69. Fraser, J. D.; Irving, B. A.; Crabtree, G. R.; Weiss, A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991, 251, 313-316.
70. Carbone, E.; Neri, P.; Mesuraca, M.; Fulciniti, M. T.; Otsuki, T.; Pende, D.; Groh, V.; Spies, T.; Pollio, G.; Cosman, D.; Catalano, L.; Tassone, P.; Rotoli, B.; Venuta, S. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005, 105, 251-258.
71. Hayashi, T.; Hideshima, T.; Akiyama, M.; Podar, K.; Yasui, H.; Raje, N.; Kumar, S.; Chauhan, D.; Treon, S. P.; Richardson, P.; Anderson, K. C. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol. 2005, 128, 192-203.
72. Pfeilschifter, J.; Chenu, C.; Bird, A.; Mundy, G. R.; Roodman, G. D. Interleukin-1 and tumour necrosis factor stimulate the formation of human osteoclast like cells in vitro. J. Bone Miner Res. 1989, 4, 113-118.
73. Hjertner, O.; Torgersen, M. L.; Seidel, C.; Hjorth-Hansen, H.; Waage, A.; Borset, M.; Sundan, A. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999, 94, 3883-3888.
74. Cavo, M.; Zamagni, E.; Tosi, P.; Tacchetti, P.; Cellini, C.; Cangini, D.; de Vivo, A.; Testoni, N.; Nicci, C; Terragna, C.; Grafone, T.; Perrone, G.; Ceccolini, M.; Tura, S.; Baccarani, M. Bologna 2002 study. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005, 106, 35-39.
75. Chauhan, D.; Uchiyama, H.; Akbarali, Y.; Urashima, M.; Yamamoto, K.; Libermann, T. A.; Anderson, K. C. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996, 87, 1104-1112.
76. Ogata, A.; Chauhan, D.; Teoh, G.; Treon, S. P.; Urashima, M.; Schlossman, R. L.; Anderson, K. C. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol. 1997, 159, 2212-2221.
77. Hideshima, T.; Chauhan, D.; Podar, K.; Schlossman, R. L.; Richardson, P.; Anderson, K. C. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin. Oncol. 2001, 28, 607-612.
78. Podar, K.; Tai, Y. T.; Davies, F. E.; Lentzsch, S.; Sattler, M.; Hideshima, T.; Lin, B. K.; Gupta, D.; Shima, Y.; Chauhan, D.; Mitsiades, C.; Raje, N.; Richardson, P.; Anderson, K. C. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001, 98, 428-435.
79. Gabrilovich, D. I.; Chen, H. L.; Girgis, K. R.; Cunningham, H. T.; Meny, G. M.; Nadaf, S.; Kavanaugh, D.; Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2, 1096-1103.
80. Hideshima, T.; Chauhan, D.; Richardson, P.; Mitsiades, C.; Mitsiades, N.; Hayashi, T.; Munshi, N.; Dang, L.; Castro, A.; Palombella, V.; Adams, J.; Anderson, K. C. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 2002, 277, 16639-16647.
81. Giuliani, N.; Bataille, R.; Mancini, C.; Lazzaretti, M.; Barille, S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001, 98, 3527-3533.
82. Standal, T.; Seidel, C.; Hjertner, O.; Plesner, T.; Sanderson, R. D.; Waage, A.; Borset, M.; Sundan, A. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002, 100, 3002-3007.
83. Croucher, P. I.; Shipman, C. M.; Lippitt, J.; Perry, M.; Asosingh, K.; Hijzen, A.; Brabbs, A. C.; van Beek, E. J.; Holen, I.; Skerry, T. M.; Dunstan, C. R.; Russell, G. R.; Van Camp, B.; Vanderkerken, K. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001, 98, 3534-3540.
84. Han, J. H.; Choi, S. J.; Kurihara, N.; Koide, M.; Oba, Y.; Roodman, G. D. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001, 97, 3349-3353.